StartRIGHT: A Pilot Research Study About Diabetes Diagnosis & Treatment
NCT02287506 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 34
Last updated 2019-09-17
Summary
This study aims to achieve more accurate early classification of diabetes and identification of which patients will rapidly require insulin treatment. The investigators will recruit 1000 participants who have been diagnosed with diabetes in the last year and were aged between 18 and 50 years at the time of diagnosis. The investigators will recruit an additional cohort of 400 participants diagnosed after age 50 treated with insulin at recruitment. The investigators will record clinical features and biomarkers that may help us to determine diabetes type at diagnosis and follow participants for 3 years to assess the development of severe insulin deficiency (measured using C-peptide) and insulin requirement. The investigators will assess utility of clinical features and additional biomarkers in identifying patients with rapid progression to insulin requirement. Findings will be integrated into a freely available clinical prediction model.
Conditions
Interventions
- OTHER
-
Optimised Diagnostic Strategy
(ODS) based on integrating Clinical information (a validated clinical probability model), Biomarkers (GAD, IA2 and ZnT8 autoantibodies) and Genetic testing for MODY
Sponsors & Collaborators
-
Royal Devon and Exeter NHS Foundation Trust
lead OTHER
Principal Investigators
-
Andrew T Hattersley, Professor · RD&E NHS FT
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 50 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2015-08-28
- Primary Completion
- 2016-05-31
- Completion
- 2016-05-31
More Related Trials
-
Assessment of Dapagliflozin on Vascular Health in Patients With Type 2 Diabetes
NCT05139914 ·Status: TERMINATED ·Phase: PHASE4
-
A Pragmatic Randomized Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients
NCT02616666 ·Status: COMPLETED ·Phase: PHASE4
-
Empaglifozin in Early Diabetic Kidney Disease
NCT03173963 ·Status: WITHDRAWN ·Phase: PHASE3
-
Sodium-glucose Co-transporter 2 (SGLT2) Inhibitor Risk of Below-Knee Lower Extremity Amputation: A Retrospective Cohort Study Using a Large Claims Database in the United States
NCT02857764 ·Status: COMPLETED
-
Effect of Rifampin on the Pharmacokinetics of Dapagliflozin in Healthy Subjects
NCT01068756 ·Status: TERMINATED ·Phase: PHASE1
-
CANVAS - CANagliflozin cardioVascular Assessment Study
NCT01032629 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Effect of Dapagliflozin on Blood Glucose Level and Renal Safety in Patients With Type 2 Diabetes
NCT02413398 ·Status: COMPLETED ·Phase: PHASE3
-
SGLT2 Inhibitors As First Line Therapy to Prevent Renal Decline in Type 2 Diabetes
NCT05345327 ·Status: RECRUITING ·Phase: PHASE3
-
Health Outcomes of Patients With Type 2 Diabetes Treated With Dapagliflozin in Conjunction With Insulin
NCT02899949 ·Status: COMPLETED
-
Safety and Effectiveness of SGLT-2 Inhibitors in Patients With Heart Failure and Diabetes
NCT02397421 ·Status: COMPLETED ·Phase: PHASE4
-
Cardiovascular Outcomes in Participants With Type 2 Diabetes Mellitus (T2DM)
NCT03249506 ·Status: COMPLETED
-
Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease
NCT06217302 ·Status: RECRUITING ·Phase: PHASE3
-
A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease
NCT03492580 ·Status: COMPLETED
-
Defining the Molecular and Physiological Mechanisms of Pancreatic Islet Cell Dysfunction Which Lead to Type 2 Diabetes
NCT02505308 ·Status: COMPLETED ·Phase: NA
-
A Study of RTA 402 in Chronic Kidney Disease (CKD) Patients With Type 2 Diabetes Mellitus
NCT01574365 ·Status: TERMINATED ·Phase: PHASE2
-
Effect of Dapagliflozin on Vascular Functions in Patients With Type 2 Diabetes Compared to Gliclazide
NCT02610088 ·Status: COMPLETED ·Phase: PHASE4
-
Prevention of Renal Failure in People Followed for Type 2 Diabetes in General Practice
NCT05749679 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
PROTOCOL 3: Role of the Renal Nerves in the Increase in EGP in Response to Glucosuria
NCT03168295 ·Status: COMPLETED ·Phase: PHASE4
-
A Glomerular Filtration Rate (GFR) Measuring Study of RTA 402 in Chronic Kidney Disease (CKD) Patients With Type 2 Diabetes Mellitus
NCT01572610 ·Status: TERMINATED ·Phase: PHASE2
-
Effects Of Sodium Glucose Cotranspoter 2 Inhibitors On Heart And Kidneys In Fabry Disease Patients
NCT05710367 ·Status: UNKNOWN ·Phase: PHASE2
-
Diastolic Dysfunction in Patients With Type 2 Diabetes Mellitus
NCT01888796 ·Status: TERMINATED ·Phase: PHASE3
-
Evaluate the Effects of Dapagliflozin in Patients With Type 2 Diabetes
NCT03269058 ·Status: COMPLETED ·Phase: PHASE4
-
Antiproteinuric Effects of Liraglutide Treatment
NCT02545738 ·Status: COMPLETED ·Phase: PHASE4
-
Diabetic Patients With End-Stage Renal Disease
NCT00435786 ·Status: COMPLETED
-
Effect of Renal Impairment on the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Ertugliflozin in Participants With Type 2 Diabetes Mellitus (MK-8835-009)
NCT01948986 ·Status: COMPLETED ·Phase: PHASE1